Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02381886 · ClinicalTrials.gov registry record · Phase 1
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase 1 study of Advanced Malignancies That Harbor IDHR132 Mutations, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
- 16
- Study locations
NCT02381886: Active Phase 1 study of Advanced Malignancies That Harbor IDHR132 Mutations, sponsored by Novartis Pharmaceuticals.
NCT02381886 is a Phase 1 study of Advanced Malignancies That Harbor IDHR132 Mutations that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 166 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (177% higher). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02381886, a Phase 1 study of Advanced Malignancies That Harbor IDHR132 Mutations, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
- 16
- Study locations
Study Summary
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
Primary Outcome
To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE)
Conditions Studied
Interventions
- DRUG IDH305
Study Locations (16)
Other
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Heidelberg
- ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55 - Rotterdam
- Novartis Investigative Site - Singapore
Massachusetts
- Dana Farber Cancer Institute SC (1) - Boston
- Dana Farber Cancer Institute - Boston
New York
- Columbia University Medical Center- New York Presbyterian Onc Dept. - New York
- Columbia University Medical Center - New York
Victoria
- Novartis Investigative Site - Melbourne
- Novartis Investigative Site - Parkville
Texas
- Uni Of TX MD Anderson Cancer Cntr - Houston
Ontario
- Novartis Investigative Site - Toronto
North Rhine-Westphalia
- Novartis Investigative Site - Cologne
Thuringia
- Novartis Investigative Site - Jena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2015-03-06 |
| Est. Completion | 2027-02-10 |
| Phase | Phase 1 |
What the registry record for NCT02381886 still lists
NCT02381886 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (177% higher).
The record links to 1 condition, with Advanced Malignancies That Harbor IDHR132 Mutations appearing as the primary indexed condition, and to 1 intervention - of which IDH305 is the first listed.
NCT02381886 lists 16 locations in 10 states (Other, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT02381886 about?
NCT02381886 is a clinical study titled "A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations". A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
What is the current status of trial NCT02381886?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2015-03-06. Estimated completion is 2027-02-10.
What conditions does trial NCT02381886 study?
This clinical trial studies the following conditions: Advanced Malignancies That Harbor IDHR132 Mutations.
What interventions are being tested in trial NCT02381886?
The interventions under investigation include: IDH305 (DRUG).
Who is sponsoring clinical trial NCT02381886?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02381886 being conducted?
This trial has 16 study locations across Massachusetts, New York, Texas, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02381886's enrollment target sits among peer trials
166 330th of 2000 higher than 1,669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI